Evox Therapeutics is harnessing and engineering the natural delivery capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. 


By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institute - the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe diseases, with profound implications for human health.

Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University and Associate Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institute, to capitalize on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs.

Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox’s mission is to positively impact human health by creating a novel exosome-based biotherapeutic modality for the treatment of a broad set of diseases and conditions with limited options for patients and their families.


Transformational therapeutics

Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.